MedWatch

Analyst: Veloxis move makes sense

With a tight funding situation and no immediate prospects of breaking into the US market with its lead product, it was only natural that Veloxis opted to uproot and move its entire organization to the US, says healthcare analyst Thomas Bowers.

Foto: Colourbox

Denmark’s Veloxis Pharmaceuticals has decided to close its office in Hørsholm, Denmark, and move all activities to the U.S. where most of the company’s current activities are already located, the company said in a press release Wednesday.

The move, which is expected to be completed during the second half of 2016, is unsurprising, says Danske Bank’s healthcare analyst, Thomas Bowers.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

ALK skifter topchef i Nordamerika

ALK’s amerikanske topchef, Jorge Alderete, har sagt sin stilling op efter næsten 23 år i selskabet. Som afløser har allergikoncernen udpeget en mand fra egne rækker.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier